The Mesothelioma Center News – Page 13
-
news
Legislation & LitigationAn acclaimed health clinic in a small Montana mining town known for treating asbestos patients has been ordered to pay almost $6 million in… -
news
Research & Clinical TrialsMesothelioma Immunotherapy Receives Orphan Drug Designation
A novel therapy for mesothelioma has been given orphan drug designation by the U.S. Food and Drug Administration. Avenge Bio, a biotechnology company working… -
news
Legislation & LitigationMesothelioma Baby Powder Lawsuit Costs J&J $18.8 Million
A jury has ruled that Johnson & Johnson must pay $18.8 million in monetary damages to a California man who developed mesothelioma after long-time… -
news
Legislation & LitigationJ&J Sues Researchers Over Studies of Asbestos in Talc Â
Johnson & Johnson is suing doctors who published studies connecting the company’s talc-based personal care products to cancer. LTL Management, a newly-formed subsidiary that… -
news
Research & Clinical TrialsResearchers Use Marine Bacteria to Reduce Asbestos Toxicity
Researchers from the University of Pennsylvania’s Department of Earth and Environmental Science have found that bacteria from extreme marine environments may potentially detoxify asbestos. -
news
Legislation & LitigationEPA Finalizes Comprehensive Asbestos Reporting Rule
On July 6, the U.S. Environmental Protection Agency announced its final rule requiring comprehensive reporting on asbestos. The new directive, issued under the Toxic… -
news
Legislation & LitigationJury Finds Libby CARD Clinic Guilty of Filing False Asbestos Health Claims
The Center for Asbestos Related Disease, located in a small Montana mining town and current asbestos Superfund site, is now entangled in fraudulent asbestos… -
news
Legislation & LitigationJ&J Must Stop Claiming Plaintiff Support of $8.9B Talc Settlement
A federal bankruptcy judge ordered a lawyer for Johnson & Johnson to stop making unsubstantiated claims about support for an $8.9 billion settlement for… -
news
Research & Clinical TrialsPhase 3 Keytruda, Chemotherapy Mesothelioma Trial Shows Promising Results
Pharmaceutical company Merck says use of its immunotherapy drug Keytruda in conjunction with chemotherapy increases the survival rate for people with advanced pleural… -
news
Asbestos Exposure & BansUK Parliament, Riddled With Asbestos, Faces Restoration Delays
Lawmakers say that Britain’s Palace of Westminster is at risk of demolition because the iconic and historic structure needs several costly repairs, including…